Previous Article | Next Article 
Journal of Virology, May 2001, p. 4176-4183, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4176-4183.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Genetic Targeting of an Adenovirus Vector via
Replacement of the Fiber Protein with the Phage T4
Fibritin
Victor
Krasnykh,1,2
Natalya
Belousova,1
Nikolay
Korokhov,2
Galina
Mikheeva,2 and
David
T.
Curiel1,*
Division of Human Gene Therapy, Departments
of Medicine, Pathology and Surgery, and the Gene Therapy Center,
University of Alabama at Birmingham,1 and
VectorLogics, Inc.,2 Birmingham, Alabama
35294
Received 27 October 2000/Accepted 2 February 2001
 |
ABSTRACT |
The utility of adenovirus (Ad) vectors for gene therapy is
restricted by their inability to selectively transduce disease-affected tissues. This limitation may be overcome by the derivation of vectors
capable of interacting with receptors specifically expressed in the
target tissue. Previous attempts to alter Ad tropism by genetic
modification of the Ad fiber have had limited success due to structural
conflicts between the fiber and the targeting ligand. Here we present a
strategy to derive an Ad vector with enhanced targeting potential by a
radical replacement of the fiber protein in the Ad capsid with a
chimeric molecule containing a heterologous trimerization motif and a
receptor-binding ligand. Our approach, which capitalized upon the
overall structural similarity between the human Ad type 5 (Ad5) fiber
and bacteriophage T4 fibritin proteins, has resulted in the generation
of a genetically modified Ad5 incorporating chimeric fiber-fibritin
proteins targeted to artificial receptor molecules. Gene transfer
studies employing this novel viral vector have demonstrated its
capacity to efficiently deliver a transgene payload to the target cells
in a receptor-specific manner.
 |
INTRODUCTION |
Human adenoviruses (Ad) of serotypes
2 and 5 (Ad2 and Ad5) have been extensively used for a variety of gene
therapy applications. This is largely due to the ability of these
vectors to efficiently deliver therapeutic genes to a wide range of
different cell types. However, the promiscuous tropism of Ad resulting
from the widespread distribution of its primary cellular receptor, the
coxsackievirus and Ad receptor (CAR) (1, 28), limits the
utility of Ad vectors in those clinical contexts where selective
delivery of a therapeutic transgene to diseased tissue is required.
Uncontrolled transduction of normal tissues with Ad vectors expressing
potentially toxic gene products may lead to a series of side effects,
thereby undermining the efficacy of the therapy. Furthermore, cellular
targets expressing CAR below certain threshold levels are not
susceptible to Ad-based therapies due to their inability to support Ad
infection. Therefore, the dependence of the efficiency of the
Ad-mediated cell transduction on the levels of CAR expression by the
target cell presents a serious challenge for the further development of
Ad-based gene therapeutics.
In order to overcome this limitation, the concept of genetic targeting
of Ad vectors to specific cell surface receptors has been proposed.
Strategies to retarget Ad vectors are based on the currently accepted
model of Ad infection (for a review, see reference 16),
which postulates that the initial binding of the Ad virion to the cell
is mediated by the attachment of the globular knob domain of the Ad
fiber protein to CAR. This is then followed by an internalization step
triggered by the interaction of the RGD-containing loop of a second Ad
capsid protein, the penton base, with cellular integrins. Although
recent studies have shown that representatives of different Ad
serotypes may utilize cell receptors other than CAR, the two-step
mechanism of cell entry established for Ad2 and Ad5 appears to be
common to the majority of human Ad serotypes. As the fiber protein is the key mediator of the cell attachment pathway employed by Ad, genetic
incorporation of targeting ligands within this viral protein was
originally proposed as the strategy to derive targeted, cell type-specific Ad vectors (21).
Each of the rodlike fiber proteins localized at the vertices of
icosahedral Ad5 capsid is a homotrimer which consists of three identical copies of a 62-kDa polypeptide (for a review see reference 4). This trimeric molecule has a domain organization, with each domain playing important roles in the structure and function of
the virion. Whereas the amino-terminal tail domain is responsible for
association of the fiber with the penton base, the carboxy-terminal knob domain, which has a propellerlike structure formed by two
-sheets (34), performs two distinct functions, both
vital for virus assembly and propagation. In addition to forming the
CAR-binding site, which is formed by residues from the AB loop,
-strand B, and the DE loop (for details, see reference
25), the knob initiates and maintains the trimerization of
the entire fiber molecule. This trimerization is critical for the
successful formation of the virion, as monomeric fibers cannot
associate with the penton base (24). The knob and the tail
of the fiber are connected by the
-spiral shaft domain
(30), which extends the knob away from the surface of the
virion, thereby facilitating interaction with CAR.
Early attempts to generate Ad vectors possessing expanded tropism
involved incorporation of short peptide ligands into either the carboxy
terminus (32, 33) or the so-called HI loop
(7) of the knob of the Ad fiber protein. Although these
studies demonstrated the feasibility of genetic targeting of Ad and
showed the potential utility of such vectors in the context of several
disease models (14, 29), further progress in this
direction has been hampered by the structural conflicts often observed
as a result of modification of the fiber structure (33).
Due to the rather complex structure of the fiber knob domain, even
minor modifications to this portion of the molecule may destabilize the
fiber, thereby rendering it incapable of trimerization and hence
nonfunctional. According to the published data, the upper size limit
for a targeting ligand to be incorporated into Ad5 fiber is about 30 amino acid residues (13, 33), which dramatically narrows
the repertoire of targeting moieties, thereby restricting the choice of
potential receptors and, therefore, cell targets. As a result of this
limitation, only a handful of heterologous peptide ligands
[oligolysine, FLAG, RGD-4C, RGS(His)6, and HA epitope]
have been successfully used in the context of Ad5 fiber modification.
The task of Ad targeting is further complicated by the need to ablate
the native receptor-binding sites within the fiber of an Ad vector to
make it truly targeted.
This study presents an alternative approach to Ad targeting based on
replacement of the native fiber in an Ad capsid with a chimeric
protein, which results in permanent ablation of native Ad receptor
tropism and simultaneously offers flexibility in the generation of
novel vector tropism.
 |
MATERIALS AND METHODS |
Cell lines.
The 293 human kidney cell line transformed with
Ad5 DNA was purchased from Microbix (Toronto, Ontario, Canada). The
211B cell line, a derivative of 293 which constitutively expresses the
Ad5 fiber protein (31), was obtained from Dan Von Seggern
(The Scripps Research Institute, La Jolla, Calif.). The 293/6H cell
line was generated by transfection of 293 cells with the plasmid vector to express an artificial receptor capable of binding proteins containing carboxy-terminal six-histidine tags (8). All
cell lines were grown at 37°C in Dulbecco's minimal essential medium (DMEM)-F12 medium supplemented with 10% fetal bovine serum in a
humidified atmosphere of 5% CO2.
Genetic engineering.
All recombinant DNA molecules generated
in this study were designed by standard methods of genetic engineering
(described in reference 26). Restriction endonucleases, T4
DNA ligase, and Klenow enzyme were from New England Biolabs (Beverly,
Mass.). PCR was performed with Pfu DNA polymerase purchased
from Stratagene (La Jolla, Calif.). In order to PCR amplify segments of
the fibritin gene, bacteriophage T4 DNA obtained from Sigma (St. Louis,
Mo.) was used as a template. Recombinant Ad genomes were derived by homologous DNA recombination in Escherichia coli BJ5183
essentially as described previously (3). Details of all
DNA manipulation experiments are available upon request.
Bacterial expression of recombinant fibritin proteins.
Recombinant forms of the fibritin-derived proteins bearing six-His tags
were expressed in E. coli M15(pREP4) cells by using vectors
of the pQE series (Qiagen, Valencia, Calif.). Induction of protein
expression and subsequent purification by immobilized metal ion
affinity chromatography of recombinant products on Ni-nitrilotriacetic acid (NTA)-agarose were done according to the manufacturer's recommendations.
Ad vectors.
Firefly luciferase-expressing Ad utilized in
this study, Ad5Luc1 and Ad5LucFF/6H, are first-generation vectors with
E1 deleted based on human Ad serotype 5. The viruses were rescued by
transfection of either 293 (12) or 211B (31)
cells with recombinant Ad genomes generated in E. coli. The
particle titer of CsCl-purified viruses amplified in 293 or 211B cells
was determined as described by Mittereder et al. (23),
whereas the infectious titer of the vectors was obtained in a spot
assay as developed by Bewig and Schmidt (2).
ELISA.
Two-hundred-nanogram aliquots of soluble CAR protein
(sCAR) (6) were adsorbed to the wells of an enzyme-linked
immunosorbent assay (ELISA) plate, unbound sCAR was aspirated, and the
wells were blocked with blocking buffer (0.05% Tween 20, 2% bovine
serum albumin in phosphate-buffered saline [PBS]). Purified viruses diluted in blocking buffer to concentrations ranging from 0.12 to 10 µg/ml were added to the wells in 100-µl aliquots and allowed to
bind with the receptor for 1 h. The plate was washed with washing buffer (0.05% Tween 20, 0.5% bovine serum albumin in PBS), and the
bound virus was probed with the rabbit anti-Ad2 serum (American Type
Culture Collection, Manassas, Va.). Following incubation for another
hour, the wells were washed, incubated with goat anti-rabbit immunoglobulin G conjugated to horseradish peroxidase (DAKO,
Carpinteria, Calif.), washed again, and developed with
o-phenylenediamine (Sigma) as recommended by the
manufacturer. The absorbance of samples at 490 nm was then determined
with a microtiter plate reader.
Gene transfer experiments.
Cells grown in the wells of
24-well plates to 90 to 100% confluence were washed with DMEM-F12-2%
fetal calf serum and then infected for 30 min with an Ad vector diluted
in 0.4 ml of the same medium. The multiplicities of infection (MOIs)
were 40, 400, and 4,000 virus particles per cell. The infected
monolayers were then incubated at 37°C in an atmosphere of 5%
CO2. Twenty hours postinfection, the virus-containing
medium was aspirated and the cells were washed with PBS and lysed in
0.25 ml of Luciferase Reporter Lysis buffer (Promega, Madison, Wis.).
The luciferase activities in the cell lysates were then measured
according to the manufacturer's protocol. Each data point was set in
triplicate and calculated as the mean of three determinations.
Inhibition of Ad5LucFF/6H-mediated gene transfer to 293/6H
cells.
The inhibition experiment was done essentially as described
above for gene transfer to 293 and 293/6H cells. Prior to infection with Ad5LucFF/6H (MOI = 40 virions per cell), the cells were
incubated for 10 min at room temperature with 0.2 ml of serial 10-fold
dilutions of either recombinant fibritin or Ad5 fiber knob
(17) in PBS. Then, a 0.2-ml aliquot of vector was added to
each well, and the incubation was continued for another 30 min. The
medium containing the virus and the inhibiting protein was removed, and
the cell monolayers were washed with DMEM-F12-2% fetal calf serum and
overlaid with fresh medium. The levels of luciferase activity detected in the cell lysates 20 h postinfection were normalized to those registered in mock-infected controls.
 |
RESULTS |
Design, expression, and characterization of a recombinant
fiber-fibritin-ligand chimera.
This work was driven by the
hypothesis that genetic targeting of Ad could best be achieved by
"splitting" the functions normally performed by the knob domain of
the Ad5 fiber between two different protein moieties which would
substitute for the knob. Specifically, we chose to replace the knob of
the fiber with a heterologous trimerization motif to maintain
trimerization of the knobless fiber and to simultaneously introduce a
ligand capable of targeting the virion to a novel receptor. Therefore,
in marked contrast to the previous attempts to fit a desired ligand
into the highly complex framework of the fiber knob domain, we employed
a radical replacement of the fiber with a protein chimera, rationally
designed to carry out the fiber's functions.
The fiber-replacing molecule engineered in this study incorporated the
tail and two amino-terminal repeats of the shaft domain of the Ad5
fiber protein genetically fused with a truncated form of the
bacteriophage T4 fibritin protein, which was employed as the
heterologous trimerizing moiety in order to compensate for the knob
deletion (Fig. 1A and B). The choice of
the T4 fibritin as the component of the fiber chimera was dictated by a
number of its structural features. The fibritin protein is a product of
the wac gene, which forms the "collar" and the
"whiskers" of the T4 capsid, where it mediates assembly of the long
tail fibers and their subsequent attachment to the tail baseplate.
Trimerization of this rodlike, 486-amino-acid-long protein is initiated
and maintained by the short (30-amino-acid-long) carboxy-terminal domain, or "foldon," which is stabilized by a number of hydrophobic interactions and hydrogen bonds (27). The central
-helical domain of fibritin, which consists of 12 segments of
parallel triple coiled coils separated by flexible loop structures,
passively follows the trimerization initiated at the carboxy terminus
of the molecule. The trimeric structure of fibritin is extremely stable
and is not compromised by either extensive amino-terminal deletions (up
to 92% of the molecule) (19) or carboxy-terminal insertions up to at least 163 amino acids long (V. V. Mesyanzhinov, personal communication). For the purposes of this study,
it is important to mention that no receptor-binding function has been shown for fibritin.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 1.
Generation of Ad5 fiber-T4 fibritin chimera containing
targeting ligand. (A) Schema showing key components of the
fiber-fibritin-ligand chimera and their sources. The tail of the fiber
anchors the fiber-fibritin-six-His chimera in the Ad virion; a
fragment of the fibritin protein provides trimerization of the
molecule, while the six-His ligand mediates binding to an AR. (B) Amino
acid sequence and domain structure of the FF/6H chimera. FF/6H protein
is a 373-amino-acid-long molecule which consists of the amino-terminal
segment of Ad5 fiber sequence genetically fused with the
carboxy-terminal portion of the T4 fibritin protein, followed by the
linker and the six-His-containing ligand. The beginning of the third
pseudorepeat of the fiber shaft domain (GNTLSQNV) is joined
to the fibritin sequence starting with the fragment of the insertion
loop (SQN) preceding the fifth coiled-coil segment of the -helical
central domain of the fibritin (VYSRLNEIDTKQTTVESDISAIKTSI).
The sequence SQNV present in the native structures of both fusion
partners was chosen as the hinge between the two molecules in order to
minimize potential structural conflicts between the -spiral
configuration of the fiber shaft and the triple -helix of the
central domain of the fibritin. The segments of the fibritin sequence
localized between every two adjacent coiled coils are the insertion
loops which provide some degree of flexibility needed for optimal
ligand presentation. A peptide linker is incorporated between the
carboxy-terminal trimerization domain (foldon) of the fibritin and the
six-histidine-containing ligand to extend the ligand away from the
carrier protein in order to facilitate binding to the target receptor.
The domain organization of the fiber and the fibritin proteins is as
published previously by Van Raaij et al. (30) and Tao et
al. (27), respectively. (C) SDS-PAGE analysis of E. coli-expressed, immobilized metal ion chromatography-purified
FF/6H chimeric protein. Lane M, molecular mass protein ladder; lanes 1 and 2, FF/6H protein; lanes 3 and 4, wild-type Ad5 fiber. The samples
in lanes 1 and 3 were denatured by being boiled, which resulted in
degradation of trimeric proteins to monomers, while lanes 2 and 4 contain proteins in their native trimeric configuration.
|
|
In order to provide a receptor-binding ligand, we chose to incorporate
into the design of this fiber-fibritin chimera a carboxy-terminal
six-His sequence connected to the fibritin protein via a short
peptide
linker. The purpose of this maneuver was to demonstrate
the feasibility
of targeting fibritin-containing Ad vectors to
alternative cell surface
receptors by directing the modified vector
to an artificial receptor
(AR), which is expressed on the surface
of 293/6H cells previously
derived in our laboratory. The extracellular
domain of this AR is an
anti-five-His single-chain antibody, which
is genetically fused with
the transmembrane domain of the platelet-derived
growth factor receptor
(
8). In addition to receptor binding,
this six-His
sequence was employed to facilitate the detection
and purification of
the fiber-fibritin-six-His chimera, FF/6H,
and Ad virions
incorporating this
protein.
For the purposes of preliminary characterization, the FF/6H chimeric
protein was initially expressed in
E. coli and purified
on
an Ni-NTA-agarose column. Subsequent sodium dodecyl
sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) analysis of the
purified chimeric
protein proved that it is trimeric and that the FF/6H
trimers
are as stable in an SDS-containing gel as the trimers of the
wild-type
Ad5 fiber (Fig.
1C). Efficient binding of the FF/6H protein
to
a Ni-NTA-containing matrix proved that the six-His ligand was
available for binding in the context of this trimeric molecule.
According to this analysis, truncated T4 fibritin incorporated
into the
FF/6H protein was able to direct trimerization of the
chimera and also
successfully served the purposes of ligand presentation,
thereby
satisfying the two key functional criteria of an ideal
fiber-replacing
molecule.
Fiber-fibritin-ligand chimera efficiently incorporates into mature
Ad5 virions.
In order to evaluate the functional utility of the
FF/6H chimeras incorporated into a mature Ad particle, we employed
homologous DNA recombination in E. coli (15) to
insert the FF/6H-encoding gene into the genome of the firefly
luciferase-expressing Ad5 with E1 deleted, in place of the wild-type
fiber gene. The virus of interest, Ad5LucFF/6H, was then rescued by
transfection of 211B cells with the resultant Ad genome. 211B cells, a
derivative of 293 cells which constitutively express the wild-type Ad5
fiber protein (31), were chosen for this transfection
experiment in order to guarantee the success of the viral rescue.
Ad5LucFF/6H was further expanded on 211B cells and purified by double
banding in a CsCl gradient. At this point, the virus stock contained
mosaic virions bearing a mixture of the wild-type fibers and FF/6H
chimeras (data not shown). In order to obtain a homogenous population
of Ad5LucFF/6H virions lacking the wild-type fibers, but exclusively incorporating FF/6H proteins, the original virus stock was then used to
infect 293/6H cells at an MOI of 1,000 virus particles per cell. CsCl
gradient purification of Ad5LucFF/6H virions isolated from the lysates
of infected 293/6H cells 72 h postinfection (at which point a complete
cytopathic effect was observed) resulted in a yield of 3 × 104 virus particles per cell, which is well within the
range of yields characteristic for Ad5 vectors with E1 deleted.
Our next goal was to demonstrate that the FF/6H chimeras had been
incorporated into the Ad5LucFF/6H capsids. Since fiberless
Ad5 virions
have been successfully purified on CsCl gradients
by others (
18,
31), it was possible that the putative Ad5LucFF/6H
virions
isolated in our study lacked FF/6H proteins. This was
ruled out by
SDS-PAGE of purified Ad5LucFF/6H virions and a Western
blot analysis
utilizing antisera specific to all three major components
of the FF/6H
chimera, the fiber tail, the fibritin, and the six-His
ligand (Fig.
2A
and B). These assays showed that the
capsid of
Ad5LucFF/6H virions consists of completely matured Ad
proteins
and incorporates full-size FF/6H chimeras. As expected, no
wild-type
fibers were found in this preparation of Ad5LucFF/6H. The
lack
of wild-type Ad5 fibers in this stock of the vector was further
confirmed by a Western blot of Ad5LucFF/6H using the anti-Ad5
fiber
knob-specific monoclonal antibody 1D6.14 (
9) (Fig.
2C).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 2.
Analysis of Ad5LucFF/6H capsid composition. (A) SDS-PAGE
of CsCl-purified Ad5LucFF/6H virions. Samples containing 4 × 1010 particles of either the wild-type Ad5 (lane 1) or
Ad5LucFF/6H (lane 2) were boiled in Laemmli sample buffer and resolved
on an SDS-10% PAGE gel. Of note, the resolution of this minigel is
not sufficient for separation of the fiber and protein IIIa, which
comigrate in lane 1. (B) Western blot analysis of FF/6H chimeras
incorporated into Ad5LucFF/6H virions. Proteins of Ad5LucFF/6H virions
denatured by being boiled in sample buffer (lanes 2) were separated on
an SDS-10% PAGE gel and then probed with the anti-Ad fiber tail MAb
4D2, the anti-five-His MAb Penta-His, and anti-fibritin mouse
polyclonal antibodies. Wild-type Ad5 (lanes 1) and Ad5LucFc6H, a virus
containing wild-type fibers with carboxy-terminal six-His tags (lanes
3), were used as controls. (C) Western blot of Ad5Luc1 and Ad5LucFF/6H
virions with anti-fiber knob antibody. Virions denatured by incubation
in a sample buffer containing SDS were resolved on an SDS-10% PAGE
gel and incubated with the anti-Ad5 fiber knob MAb 1D6.14
(9), which recognize the knob trimer. Lanes 1 and 3, Ad5LucFF/6H (3 × 109 and 6 × 109
virus particles per lane, respectively); lanes 2 and 4, Ad5Luc1 (same
amounts of the virus as in lanes 1 and 3). Detection of viral proteins
was done with the ECL Plus kit from Amersham Pharmacia Biotech
(Piscataway, N.J.).
|
|
These findings were further corroborated in an experiment involving
binding of purified Ad5LucFF/6H virions to Ni-NTA-resin;
in contrast to
the Ad vector containing wild-type fibers, which
did not bind to the
matrix, Ad5LucFF/6H clearly demonstrated six-His-mediated
binding to
the resin (Fig.
3). Therefore, in
addition to its ability
to assume a trimeric configuration and bind to
a receptor-mimicking
molecule, the FF/6H chimera also retained the
capacity to be incorporated
into mature Ad capsids.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 3.
Binding of Ad5LucFF/6H virions to Ni-NTA-agarose.
Wild-type Ad5 or Ad5LucFF/6H were incubated with an aliquot of
Ni-NTA-resin for 1 h. The matrix was pelleted by centrifugation,
and the supernatant was removed and then incubated with a second
aliquot of Ni-NTA-agarose. Aliquots of material subsequently eluted
from the resin, as well as an aliquot of the material present in the
supernatant after two sequential incubations with the resin, were
separated on an SDS-10% PAGE gel (wild-type Ad5 in lanes 1 through 4 and Ad5LucFF/6H in lanes 5 through 8) and then stained (A) or probed
with either the anti-fiber tail MAb 4D2 (B) or the anti-five-His MAb
Penta-His (C). Lane M, molecular mass marker; lanes 1 and 5, aliquot of
the virus prior to incubation with Ni-NTA-agarose; lanes 2 and 6, material bound to the first aliquot of the resin; lanes 3 and 7, material bound to the second aliquot of the resin; lanes 4 and 8, material remaining in the supernatant after two sequential bindings to
the resin. Incomplete binding of Ad5LucFF/6H virions to Ni-NTA-agarose
is most likely due to the small size of the pores in the Sepharose
CL-6B used as the matrix for manufacturing Ni-NTA-agarose. According to
the manufacturer's specifications, the size of those pores does not
allow protein molecules with a molecular mass larger that 4 MDa to
enter the pores. Thus, the Ni-NTA groups which are localized on the
surfaces of the Sepharose particles (a relatively small percentage) are
accessible to the six-His-tagged virions, whereas those hidden inside
the pores (the majority) are not.
|
|
Restriction enzyme analysis of the Ad5LucFF/6H genome, diagnostic PCR
utilizing a pair of primers flanking the fiber gene
in the Ad5 genome
(Fig.
4), and partial sequencing of
Ad5LucFF/6H
DNA all demonstrated that the viral genome was stable and
that
the only fiber-encoding gene present was the FF/6H gene. This
set
of experiments completed the molecular characterization of
Ad5LucFF/6H
by confirming both the identity and the integrity
of the virus capsid
and its genome.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of Ad5LucFF/6H genome structure. (A) DNA
isolated from purified Ad5LucFF/6H virions was subjected to restriction
enzyme analysis using a number of restriction endonucleases which
cleave either the wild-type fiber or the FF/6H gene sequence.
Odd-numbered lanes, control Ad5Luc1 DNA; even-numbered lanes,
Ad5LucFF/6H DNA. (B) Diagnostic PCR utilizing a pair of primers
flanking the fiber gene in the Ad5 genome was employed to show the
absence of the wild-type fiber gene sequence in the Ad5LucFF/6H genome.
The primers used in this test were designed to amplify both the
wild-type fiber gene (1.8 kb) and the FF/6H gene (1.1 kb). Lane 1, PCR
product amplified from wild-type Ad5 DNA; lane 2, PCR product amplified
from Ad5LucFF/6H DNA; lane M, 1-kb ladder.
|
|
Ad5LucFF/6H vector containing FF/6H protein chimeras lacks tropism
to CAR and is capable of efficient and target receptor-specific gene
delivery.
As Ad5LucFF/6H was designed for CAR-independent delivery
of transgenes to AR-expressing cells, we wished to prove that this vector is not capable of binding to CAR and that its cell attachment occurs solely via interaction with AR.
This vector's lack of CAR-binding capacity was first confirmed by an
ELISA utilizing a soluble form of the human CAR protein,
sCAR
(
6), and purified Ad virions. As expected, this assay
showed that in contrast to the Ad vector incorporating wild-type
Ad5
fibers (Ad5Luc1, which binds to sCAR in an efficient, dose-dependent
manner), Ad5LucFF/6H clearly fails to bind CAR (Fig.
5A). This
lack of Ad5LucFF/6H tropism to
CAR was further confirmed in a
gene transfer experiment employing
E. coli-expressed Ad5 fiber
knob protein (
17)
as a CAR-blocking competitor. By binding to
CAR present on 293/6H
cells, the knob protein blocked 91 and 98%
of Ad5Luc1-mediated gene
delivery at concentrations of 1 and 10
µg/ml, respectively, whereas
no significant inhibition was seen
for the Ad5LucFF/6H vector (Fig.
5B). In the aggregate, these
data proved the inability of Ad5LucFF/6H
to bind to cognate Ad5
receptor and, therefore, to use the native
mechanism of cell attachment.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 5.
Analyses of Ad5LucFF/6H binding to CAR. (A) ELISA
employing recombinant human sCAR protein. Baculovirus-expressed sCAR
protein adsorbed on an ELISA plate was incubated with various amounts
of purified Ad virions. Virions bound to sCAR were then detected with
anti-Ad2 polyclonal antibody. Each point represents a mean of three
readings obtained in one experiment, with the error bars showing
standard deviations. The background, which was equal to 0.06, has been
subtracted from all data points. (B) Ad5 fiber knob-mediated inhibition
of 293/6H cell transduction. 293/6H cells expressing AR and grown in
the wells of a 24-well plate were preincubated with PBS or E. coli-expressed recombinant Ad5 fiber knob protein at
concentrations of 1 and 10 µg/ml prior to infection with the Ad
vectors. Luciferase activities detected in the lysates of cells
infected in the presence of the knob are shown as percentages of the
activity registered in cells in which infection was blocked with the
inhibitor. Each data point corresponds to an average of three
measurements less the background. The error bars show the standard
deviations.
|
|
We next sought to test whether the six-His tags of the fiber-fibritin
proteins incorporated into Ad5LucFF/6H virions are capable
of
functioning as receptor-binding ligands and mediating binding
to AR
expressed by 293/6H cells (
8). This was addressed by
another gene transfer experiment employing two different forms
of
recombinant fibritin proteins as blocking agents, only one
of which,
fibritin-6H, contained a carboxy-terminal six-His tag
(Fig.
6A). The purpose of using fibritin, which
lacks the carboxy-terminal
tag, was to provide additional evidence that
the backbone of the
fibritin molecule does not contribute to binding to
the AR or
any other cell surface receptor. Dose-dependent inhibition of
Ad5LucFF/6H infection of 293/6H cells with fibritin-6H, but not
with
the fibritin lacking the six-His tag, proved that this ligand
is the
component of the virion solely responsible for binding
of the virus to
target cells.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 6.
Evaluation of the efficiency and receptor specificity of
Ad5LucFF/6H-mediated gene transfer. (A) Specificity of Ad5LucFF/6H
binding to the AR. 293/6H cells grown in monolayer culture were
preincubated with various concentrations of either the truncated form
of fibritin or fibritin carrying a carboxy-terminal six-His tag,
fibritin-6H, prior to infection with Ad5LucFF/6H. Luciferase activities
detected in the lysates of infected cels 20 h postinfection are given
as percentages of the activity in the absence of blocking protein. (B)
Gene transfer to 293 and 293/6H cells. Cells seeded in 24-well plates
were infected with various doses of Ad5Luc1 or Ad5LucFF/6H. The MOI was
equal to 40, 400, or 4,000 virus particles per cell. Twenty hours
postinfection, the cells were collected and lysed, and the luciferase
activities of the lysates were measured in relative light units (rlu).
On both graphs, each data point was set in triplicate and calculated as
the mean of three determinations. The error bars show standard
deviations.
|
|
We then wished to compare the efficiency of the cell entry pathway used
by Ad5LucFF/6H with the natural, CAR-mediated mechanism
of cell
attachment utilized by unmodified Ad vectors. Based on
the significant
difference in the dissociation constants (
kd)
previously determined for the Ad5 fiber-CAR interaction, 4 × 10
9 M (
5), and for the
five-His-anti-five-His monoclonal antibody
(MAb) 3D5 interaction,
4.75 × 10
7 M (
20), we anticipated
lower efficiency of the AR-mediated
cell entry pathway compared to the
native route of Ad infection.
With these considerations in mind, in the
next gene transfer experiment
we used both vectors at MOIs ranging from
40 to 4,000 virus particles
per cell in order to compare the results
obtained for the two
vectors at various virus doses. The doses of both
viruses were
normalized by the particle titers of the virus
preparations. Although
this experiment showed that Ad5LucFF/6H was
capable of efficient
transgene delivery to the target cells, it also
revealed that
at equal MOIs the levels of transgene expression in
Ad5Luc1-infected
293/6H cells were 9.5- to 77-fold higher than those
registered
in 293/6H cells infected with Ad5LucFF/6H. Importantly,
there
was an increase of 2 orders of magnitude in Ad5LucFF/6H-expressed
luciferase activities detected in 293/6H cells expressing AR compared
to that in parental 293 cells infected with the same vector.
Transduction
of 293 cells revealed a 1,300- to 6,900-fold difference in
luciferase
expression in the Ad5Luc1- and Ad5LucFF/6H-infected cells.
The
poor transduction of 293 cells by Ad5LucFF/6H further proved the
inability of this vector with the fiber deleted to use CAR, which
is
abundantly expressed by these cells (
7), for cell
attachment.
In order to find out whether the replication of Ad5Luc1 and Ad5LucFF/6H
in 293/6H cells had any confounding effect on the
relative efficiencies
of their gene transfer capabilities, we
compared the infectivities of
these vectors on 293/6H cells by
using the spot assay developed by
Bewig and Schmidt (
2). This
technique excludes any
potential effects of viral replication
on the ratio of the vectors'
transduction capacities, thereby
providing a direct measure of Ad
infectivity. According to this
assay, the differential between the
capacities of these vectors
to infect 293/6H cells was equal to 51, which is similar to that
observed earlier in our gene transfer
experiments.
Taken together, these data strongly suggest that as a result of the
replacement of the fiber in the Ad5LucFF/6H capsid with
the FF/6H
chimera, this vector possesses the capacity to achieve
cell infection
in a CAR-independent, receptor-specific manner
via interaction of the
virus with the
AR.
 |
DISCUSSION |
In this study, we have developed a novel approach to the
modification of Ad vector tropism by replacing the receptor-binding fiber protein in the Ad capsid with an artificial protein chimera. The
rational design of this chimera, based on the general structural similarity of the Ad5 fiber and bacteriophage T4 fibritin, has resulted
in the derivation of a novel ligand-presenting molecule. The most
important difference between this protein and the wild-type fiber is
the disengagement of the trimerization and the receptor-binding functions normally performed by the fiber knob domain. As a result of
this distribution of functions, the receptor specificity of the
reengineered Ad5 vector may now be defined by a domain of the chimera
which plays no role in the trimerization of the molecule and may
therefore be manipulated without the risk of destabilizing the
ligand-presenting protein and the virion. Previous successful reports
of the use of T4 fibritin for ligand display (10, 22) suggest that a wide variety of heterologous targeting ligands, including large polypeptide molecules, could be employed in the context
of the fiber-fibritin chimera described here.
Fibritin chimeras analogous to the one described in this work may be
viewed as versatile ligand-displaying molecules suitable for the
genetic modification of virtually any human or animal Ad vector. The
problem of the elimination of undesirable natural tropism of native
fibers contained in the Ad virion may thus be solved by replacement of
native fibers with such fibritin chimeras. This approach has a
significant advantage over maneuvers involving the identification and
subsequent mutagenesis of the native receptor-binding sites within the
fibers of numerous Ad species, some of which are able to bind to
different types of primary receptors. In addition, the strategy of
fiber replacement eliminates the risk of reversion of the mutated fiber
gene to the wild type during multiple rounds of propagation, which, if
it happened, would compromise the efficiency of any vector targeting schema.
An additional advantage offered by Ad vectors incorporating the
fibritin-based chimeras for the purposes of human gene therapy becomes
apparent in light of recently published data on interference of
anti-fiber antibodies present in the sera of some gene therapy patients
with the Ad vectors used in clinical protocols (11). Importantly, these antibodies have been shown to have a synergistic effect on Ad vector neutralization when present together with anti-penton base antibodies. Thus, deletion of most of the fiber sequence in the fibritin-bearing Ad vectors would make them refractory to this type of immune response and therefore more efficient as therapeutic agents.
 |
ACKNOWLEDGMENTS |
We thank V. Mesyanzhinov for providing anti-fibritin antibody and
for sharing with us unpublished data on carboxy-terminal modifications
of the fibritin protein. D. Von Seggern is thanked for generously
providing 211B cells. We are grateful to I. Dmitriev for making
recombinant Ad5 fiber and sCAR proteins available to us. We are
indebted to J. T. Douglas for stimulating discussions, as well as for
providing 1D6.14 for our studies.
This work was supported by the following grants: NCI N01 CO-97110, NIH
R01 CA74242, NIH R01 HL50255, and NIH R01 CA83821.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 1824 Sixth Ave.
South, WTI 620, Birmingham, AL 35294. Phone: (205) 934-8627. Fax: (205) 975-7476. E-mail: David.Curiel{at}ccc.uab.edu.
 |
REFERENCES |
| 1.
|
Bergelson, J. M.,
J. A. Cunningham,
G. Droguett,
E. A. Kurt-Jones,
A. Krithivas,
J. S. Hong,
M. S. Horwitz,
R. L. Crowell, and R. W. Finberg.
1997.
Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.
Science
275:1320-1323[Abstract/Free Full Text].
|
| 2.
|
Bewig, B., and W. E. Schmidt.
2000.
Accelerated titering of adenoviruses.
BioTechniques
28:870-873[Medline].
|
| 3.
|
Chartier, C.,
E. Degryse,
M. Gantzer,
A. Dieterle,
A. Pavirani, and M. Mehtali.
1996.
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.
J. Virol.
70:4805-4810[Abstract].
|
| 4.
|
Chroboczek, J.,
R. W. Ruigrok, and S. Cusack.
1995.
Adenovirus fiber.
Curr. Top. Microbiol. Immunol.
199:163-200.
|
| 5.
|
Davison, E.,
I. Kirby,
T. Elliott, and G. Santis.
1999.
The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber.
J. Virol.
73:4513-4517[Abstract/Free Full Text].
|
| 6.
|
Dmitriev, I.,
E. Kashentseva,
B. E. Rogers,
V. Krasnykh, and D. T. Curiel.
2000.
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells.
J. Virol.
74:6875-6884[Abstract/Free Full Text].
|
| 7.
|
Dmitriev, I.,
V. Krasnykh,
C. R. Miller,
M. Wang,
E. Kashentseva,
G. Mikheeva,
N. Belousova, and D. T. Curiel.
1998.
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.
J. Virol.
72:9706-9713[Abstract/Free Full Text].
|
| 8.
|
Douglas, J. T.,
C. R. Miller,
M. Kim,
I. Dmitriev,
G. Mikheeva,
V. Krasnykh, and D. T. Curiel.
1999.
A system for the propagation of adenoviral vectors with genetically modified receptor specificities.
Nat. Biotechnol.
17:470-475[CrossRef][Medline].
|
| 9.
|
Douglas, J. T.,
B. E. Rogers,
M. E. Rosenfeld,
S. I. Michael,
M. Feng, and D. T. Curiel.
1996.
Targeted gene delivery by tropism-modified adenoviral vectors.
Nat. Biotechnol.
14:1574-1578[CrossRef][Medline].
|
| 10.
|
Efimov, V. P.,
I. V. Nepluev, and V. V. Mesyanzhinov.
1995.
Bacteriophage T4 as a surface display vector.
Virus Genes
10:173-177[CrossRef][Medline].
|
| 11.
|
Gahery-Segard, H.,
F. Farace,
D. Godfrin,
J. Gaston,
R. Lengagne,
T. Tursz,
P. Boulanger, and J. G. Guillet.
1998.
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.
J. Virol.
72:2388-2397[Abstract/Free Full Text].
|
| 12.
|
Graham, F. L.,
J. Smiley,
W. C. Russell, and R. Nairn.
1977.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J. Gen. Virol.
36:59-74[Abstract/Free Full Text].
|
| 13.
|
Hong, J. S., and J. A. Engler.
1996.
Domains required for assembly of adenovirus type 2 fiber trimers.
J. Virol.
70:7071-7078[Abstract/Free Full Text].
|
| 14.
|
Kasono, K.,
J. L. Blackwell,
J. T. Douglas,
I. Dmitriev,
T. V. Strong,
P. Reynolds,
D. A. Kropf,
W. R. Carroll,
G. E. Peters,
R. T. Bucy,
D. T. Curiel, and V. Krasnykh.
1999.
Selective gene delivery to head and neck cancer cells via an integrin targeted adenovirus vector.
Clin. Cancer Res.
5:2571-2579[Abstract/Free Full Text].
|
| 15.
|
Krasnykh, V.,
I. Dmitriev,
G. Mikheeva,
C. R. Miller,
N. Belousova, and D. T. Curiel.
1998.
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob.
J. Virol.
72:1844-1852[Abstract/Free Full Text].
|
| 16.
|
Krasnykh, V. N.,
J. T. Douglas, and V. W. van Beusechem.
2000.
Genetic targeting of adenoviral vectors.
Mol. Ther.
1:391-405[CrossRef][Medline].
|
| 17.
|
Krasnykh, V. N.,
G. V. Mikheeva,
J. T. Douglas, and D. T. Curiel.
1996.
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.
J. Virol.
70:6839-6846[Abstract/Free Full Text].
|
| 18.
|
Legrand, V.,
D. Spehner,
Y. Schlesinger,
N. Settelen,
A. Pavirani, and M. Mehtali.
1999.
Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber.
J. Virol.
73:907-919[Abstract/Free Full Text].
|
| 19.
|
Letarov, A. V.,
Y. Y. Londer,
S. P. Boudko, and V. V. Mesyanzhinov.
1999.
The carboxy-terminal domain initiates trimerization of bacteriophage T4 fibritin.
Biochemistry
64:817-823[Medline].
|
| 20.
|
Lindner, P.,
K. Bauer,
A. Krebber,
L. Nieba,
E. Kremmer,
C. Krebber,
A. Honegger,
B. Klinger,
R. Mocikat, and A. Pluckthun.
1997.
Specific detection of His-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions.
BioTechniques
22:140-149[Medline].
|
| 21.
|
Michael, S. I.,
J. S. Hong,
D. T. Curiel, and J. A. Engler.
1995.
Addition of a short peptide ligand to the adenovirus fiber protein.
Gene Ther.
2:660-668[Medline].
|
| 22.
|
Miroshnikov, K. A.,
E. I. Marusich,
M. E. Cerritelli,
N. Cheng,
C. C. Hyde,
A. C. Steven, and V. V. Mesyanzhinov.
1998.
Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins.
Protein Eng.
11:329-332[Abstract/Free Full Text].
|
| 23.
|
Mittereder, N.,
K. L. March, and B. C. Trapnell.
1996.
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.
J. Virol.
70:7498-7509[Abstract].
|
| 24.
|
Novelli, A., and P. A. Boulanger.
1991.
Assembly of adenovirus type 2 fiber synthesized in cell-free translation system.
J. Biol. Chem.
266:9299-9303[Abstract/Free Full Text].
|
| 25.
|
Roelvink, P. W.,
G. Mi Lee,
D. A. Einfeld,
I. Kovesdi, and T. J. Wickham.
1999.
Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.
Science
286:1568-1571[Abstract/Free Full Text].
|
| 26.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 27.
|
Tao, Y.,
S. V. Strelkov,
V. V. Mesyanzhinov, and M. G. Rossmann.
1997.
Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain.
Structure
5:789-798[Abstract/Free Full Text].
|
| 28.
|
Tomko, R. P.,
R. Xu, and L. Philipson.
1997.
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.
Proc. Natl. Acad. Sci. USA
94:3352-3356[Abstract/Free Full Text].
|
| 29.
|
Vanderkwaak, T. J.,
M. Wang,
J. Gomez-Navarro,
C. Rancourt,
I. Dmitriev,
V. Krasnykh,
M. Barnes,
G. P. Siegal,
R. Alvarez, and D. T. Curiel.
1999.
An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.
Gynecol. Oncol.
74:227-234[CrossRef][Medline].
|
| 30.
|
van Raaij, M. J.,
A. Mitraki,
G. Lavigne, and S. Cusack.
1999.
A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein.
Nature
401:935-938[CrossRef][Medline].
|
| 31.
|
Von Seggern, D. J.,
J. Kehler,
R. I. Endo, and G. R. Nemerow.
1998.
Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein.
J. Gen. Virol.
79:1461-1468[Abstract].
|
| 32.
|
Wickham, T. J.,
P. W. Roelvink,
D. E. Brough, and I. Kovesdi.
1996.
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types.
Nat. Biotechnol.
14:1570-1573[CrossRef][Medline].
|
| 33.
|
Wickham, T. J.,
E. Tzeng,
L. L. Shears,
P. W. Roelvink,
Y. Li,
G. M. Lee,
D. E. Brough,
A. Lizonova, and I. Kovesdi.
1997.
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.
J. Virol.
71:8221-8229[Abstract].
|
| 34.
|
Xia, D.,
L. J. Henry,
R. D. Gerard, and J. Deisenhofer.
1994.
Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 Å resolution.
Structure
2:1259-1270[Medline].
|
Journal of Virology, May 2001, p. 4176-4183, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4176-4183.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Belousova, N., Mikheeva, G., Gelovani, J., Krasnykh, V.
(2008). Modification of Adenovirus Capsid with a Designed Protein Ligand Yields a Gene Vector Targeted to a Major Molecular Marker of Cancer. J. Virol.
82: 630-637
[Abstract]
[Full Text]
-
Gaballah, K., Hills, A., Curiel, D., Hallden, G., Harrison, P., Partridge, M.
(2007). Lysis of Dysplastic but not Normal Oral Keratinocytes and Tissue-Engineered Epithelia with Conditionally Replicating Adenoviruses. Cancer Res.
67: 7284-7294
[Abstract]
[Full Text]
-
Rajecki, M., Kanerva, A., Stenman, U.-H., Tenhunen, M., Kangasniemi, L., Sarkioja, M., Ala-Opas, M. Y., Alfthan, H., Sankila, A., Rintala, E., Desmond, R. A., Hakkarainen, T., Hemminki, A.
(2007). Treatment of prostate cancer with Ad5/3{Delta}24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Molecular Cancer Therapeutics
6: 742-751
[Abstract]
[Full Text]
-
Li, J., Lad, S., Yang, G., Luo, Y., Iacobelli-Martinez, M., Primus, F. J., Reisfeld, R. A., Li, E.
(2006). Adenovirus Fiber Shaft Contains a Trimerization Element That Supports Peptide Fusion for Targeted Gene Delivery. J. Virol.
80: 12324-12331
[Abstract]
[Full Text]
-
Henning, P., Lundgren, E., Carlsson, M., Frykholm, K., Johannisson, J., Magnusson, M. K., Tang, E., Franqueville, L., Hong, S. S., Lindholm, L., Boulanger, P.
(2006). Adenovirus type 5 fiber knob domain has a critical role in fiber protein synthesis and encapsidation.. J. Gen. Virol.
87: 3151-3160
[Abstract]
[Full Text]
-
Tyler, M. A., Ulasov, I. V., Borovjagin, A., Sonabend, A. M., Khramtsov, A., Han, Y., Dent, P., Fisher, P. B., Curiel, D. T., Lesniak, M. S.
(2006). Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus.. Molecular Cancer Therapeutics
5: 2408-2416
[Abstract]
[Full Text]
-
Sissoeff, L., Mousli, M., England, P., Tuffereau, C.
(2005). Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor. J. Gen. Virol.
86: 2543-2552
[Abstract]
[Full Text]
-
Vellinga, J., Van der Heijdt, S., Hoeben, R. C.
(2005). The adenovirus capsid: major progress in minor proteins. J. Gen. Virol.
86: 1581-1588
[Abstract]
[Full Text]
-
Mercier, G. T., Campbell, J. A., Chappell, J. D., Stehle, T., Dermody, T. S., Barry, M. A.
(2004). A chimeric adenovirus vector encoding reovirus attachment protein {sigma}1 targets cells expressing junctional adhesion molecule 1. Proc. Natl. Acad. Sci. USA
101: 6188-6193
[Abstract]
[Full Text]
-
Vellinga, J., Rabelink, M. J. W. E., Cramer, S. J., van den Wollenberg, D. J. M., Van der Meulen, H., Leppard, K. N., Fallaux, F. J., Hoeben, R. C.
(2004). Spacers Increase the Accessibility of Peptide Ligands Linked to the Carboxyl Terminus of Adenovirus Minor Capsid Protein IX. J. Virol.
78: 3470-3479
[Abstract]
[Full Text]
-
Papanikolopoulou, K., Forge, V., Goeltz, P., Mitraki, A.
(2004). Formation of Highly Stable Chimeric Trimers by Fusion of an Adenovirus Fiber Shaft Fragment with the Foldon Domain of Bacteriophage T4 Fibritin. J. Biol. Chem.
279: 8991-8998
[Abstract]
[Full Text]
-
Koizumi, N., Mizuguchi, H., Sakurai, F., Yamaguchi, T., Watanabe, Y., Hayakawa, T.
(2003). Reduction of Natural Adenovirus Tropism to Mouse Liver by Fiber-Shaft Exchange in Combination with both CAR- and {alpha}v Integrin-Binding Ablation. J. Virol.
77: 13062-13072
[Abstract]
[Full Text]
-
Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P. L., Aldrich, W. A., Banerjee, P. T., Gillies, S. D., Curiel, D. T., Krasnykh, V.
(2003). Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells. J. Virol.
77: 11367-11377
[Abstract]
[Full Text]
-
Burke, B., Sumner, S., Maitland, N., Lewis, C. E.
(2002). Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J. Leukoc. Biol.
72: 417-428
[Abstract]
[Full Text]
-
Belousova, N., Krendelchtchikova, V., Curiel, D. T., Krasnykh, V.
(2002). Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein. J. Virol.
76: 8621-8631
[Abstract]
[Full Text]
-
Hsieh, C.-L., Yang, L., Miao, L., Yeung, F., Kao, C., Yang, H., Zhau, H. E., Chung, L. W. K.
(2002). A Novel Targeting Modality to Enhance Adenoviral Replication by Vitamin D3 in Androgen-independent Human Prostate Cancer Cells and Tumors. Cancer Res.
62: 3084-3092
[Abstract]
[Full Text]
-
Kanerva, A., Mikheeva, G. V., Krasnykh, V., Coolidge, C. J., Lam, J. T., Mahasreshti, P. J., Barker, S. D., Straughn, M., Barnes, M. N., Alvarez, R. D., Hemminki, A., Curiel, D. T.
(2002). Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells. Clin. Cancer Res.
8: 275-280
[Abstract]
[Full Text]